Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
Frequently asked questions
What sector does Gongwin Biopharm Holdings Co. Ltd. (6617) operate in?
Gongwin Biopharm Holdings Co. Ltd. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Gongwin Biopharm Holdings Co. Ltd. (6617) current stock price?
As of the latest data, Gongwin Biopharm Holdings Co. Ltd. stock price is NT$102.00, with a previous close of NT$102.00.
What is Gongwin Biopharm Holdings Co. Ltd. (6617) current market capitalization?
Gongwin Biopharm Holdings Co. Ltd. market cap is approximately 12.35 billion.
What is Gongwin Biopharm Holdings Co. Ltd. (6617) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.92.
Does Gongwin Biopharm Holdings Co. Ltd. (6617) pay dividends?
No. Gongwin Biopharm Holdings Co. Ltd. does not pay a dividend.
What is Gongwin Biopharm Holdings Co. Ltd. (6617) beta (volatility) score?
Gongwin Biopharm Holdings Co. Ltd. has a beta of 0.253, indicating lower volatility than the overall market.
